Novobiocin Kills Tumor Cells | Cosela Fast-Tracked for TNBC | Systemic Review of MTB Clinical OutcomesJuly 26, 2021 | Oncology Family Medicine/General Practice Antibiotic Novobiocin Found to Kill Tumor Cells with DNA-Repair Glitch In a study in the journal Nature Cancer, the researchers found that in laboratory cell lines and tumor models novobiocin selectively killed tumor cells with abnormal BRCA1 or BRCA2 genes, which help repair damaged DNA. The drug, developed in the 1950s and largely supplanted by newer drugs, was effective even in tumors resistant to agents known as PARP inhibitors, which have become a prime therapy for cancers with DNA-repair glitches. Read full article Internal Medicine FDA Grants Fast Track Status to Cosela for Triple-Negative Breast Cancer (TNBC) Trilaciclib (Cosela, G1 Therapeutics), a cyclin dependent kinase 4/6 inhibitor, is already approved in the United States to reduce frequency of chemotherapy-related bone marrow suppression among adults with extensive-stage small cell lung cancer. Now, the FDA has granted fast track designation to the drug for use in combo with chemo for treatment of locally advanced or metastatic TNBC. Read full article Hematology Clinical Outcomes of Molecular Tumor Boards: A Systematic Review In this systematic review to evaluate the clinical outcomes associated with molecular tumor board (MTB) review in patients with cancer, 14 studies were included with a total of 3,328 patients. As the number of targetable mutations continues to increase and cancer care becomes even more complex, consultation with an interdisciplinary MTB can help guide therapy selection for patients with cancer. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS